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Background/aim: Data on antibody response following COVID-19 in kidney transplant recipients is scarce. This crosssectional study
aims to investigate the antibody response to COVID-19 among kidney transplant recipients.
Materials and methods: We recruited 46 kidney transplant recipients with RT-PCR-confirmed COVID-19 and 45 recipients without
COVID-19 history. We also constructed two control groups (COVID-19 positive and negative) from a historical cohort of healthcare
workers. We used age and sex-based propensity score matching to select the eligible subjects to the control groups. We measured the
SARS-CoV-2 IgG levels quantitatively using the Abbott ARCHITECT system. An antibody level above 1.4 S/C was defined as positivity.
Results: Transplant recipients with COVID-19 had a higher BMI, and COVID-19 history in a household member was more common
than that of the transplant recipient without COVID-19. IgG seropositivity rate (69.6% vs. 78.3%, p = 0.238) and the median IgG level
(3.28 [IQR: 0.80–5.85] vs. 4.59 [IQR: 1.61–6.06], p = 0.499) were similar in COVID-19-positive transplant recipients and controls.
Kidney transplant recipients who had a longer duration between RT-PCR and antibody testing had lower antibody levels (r = –0.532,
p < 0.001).
Conclusion: At the early post-COVID-19 period, kidney transplant recipients have a similar antibody response to controls. However,
these patients’ antibody levels and immunity should be closely monitored in the long term.
Key words: COVID-19, immune response, immunosuppression, kidney transplantation, SARS-CoV-2 IgG antibody

1. Introduction
The coronavirus disease 2019 (COVID-19) pandemic
caused by the SARS-CoV-2 virus has affected the global
health system in an unprecedented way. The rapid
development of various vaccines has become an important
milestone in combating the pandemic. Vaccination relies
on the production of antibodies via the stimulation of
humoral immunity. However, data regarding antibody
response to infection in immunosuppressed patients,
including kidney transplant recipients, is not well defined.
Different mortality rates for COVID-19 were reported
from different countries. According to a recent study in
Western countries, mortality rates changed between 4.0%
and 16.1%. Higher mortality rates were reported in patients
with kidney disease in different studies, specifically in

kidney transplantation patients having a mortality rate that
ranges between 18.0% and 41.6% [1-6]. Moreover, data
on the seropositivity rate following COVID-19 in kidney
transplant recipients are scarce and not in agreement
across studies. According to a recent study, lower antibody
response rates (41.0%) were reported in kidney transplant
recipients following recovery from the infection [7,8]. On
the other hand, Azzi et al. investigated 69 kidney transplant
recipients with reverse transcriptase-polymerase chain
reaction (RT-PCR)-confirmed COVID-19 infection and
found antinucleocapsid antibodies in 55 (80.0%) of them
[9].
Usually, higher antibody response rates were reported
for patients from the general population [8]. In a recent
study, antinucleoprotein seropositivity rate was found
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78.2% among healthcare workers with RT-PCR-confirmed
COVID-19 [10].
In this crosssectional study, we aimed to investigate
the prevalence of anti-SARS-CoV-2 antibodies in kidney
transplant recipients first. Then, we examined the factors
associated with the absence of antibody response.
2. Materials and methods
2.1. Study design
We performed a crosssectional study to recruit renal
transplant recipients who were under regular follow-up
at two university hospital’s transplantation centers (CMF
and KMF) and had RT-PCR-confirmed COVID-19. We
also recruited consecutive renal transplant recipients
who did not have a history of COVID-19 and were
attending the transplantation outpatient clinics in those
institutions. We constructed two additional control groups
from a previously screened cohort of healthcare workers
[10]. None of the included patients was vaccinated for
COVID-19 prior to the antibody measurement.
We used the descriptive comparative design method
to assess the outcomes. The study protocol was approved
by the Clinical Research Ethics Committee of İstanbul
University-Cerrahpaşa (approval no: 2021-2921) and
the Ministry of Health’s Scientific Committee (approval
no: 2020-11-30T14_57_30). The study was conducted
in accordance with the 1975 Declaration of Helsinki, as
revised in 2013.
2.2. Sampling
The study was conducted between December 7, 2020, and
February 12, 2021. The date of blood specimen collection
for antibody measurement was accepted as the enrollment
date to the study. The date of the RT-PCR testing was
accepted as the first day of infection.
2.2.1. Transplant recipients
Based on previous studies, we predicted the seropositivity
following COVID-19 as 60% for transplant recipients
[9,11] and 90% for subjects from the general population
[12-14]. We performed a power analysis, and we planned
to recruit 42 participants to each group.
A total of 623 patients had attended the outpatient
transplantation clinics during the year 2020. Our target
population comprised of patients who had COVID-19
following April, 2020. We did not formally screen all
patients under follow-up; however, all of our transplant
patients who had an RT-PCR-confirmed COVID-19
history were eligible for the study. We located 57 patients
who had COVID-19, one of them died before the start of
the study, 46 of them accepted to participate in the study.
We recruited transplant patients who gave informed
consent in the COVID-19-negative group if they have not
received a diagnosis of COVID-19 as of the recruitment
day. We also checked if they had any RT-PCR test due to

mandatory screening (before hospitalization due to any
cause, having a household member with COVID-19) and
confirmed that their RT-PCR test was negative. A total of
45 patients met the inclusion criteria for the control group.
Seventy-one of the 91 transplant recipients included in
the study received a transplant from a living donor, while
all donors were first- or second-degree relatives.
2.2.2. Controls
We recruited control subjects from a cohort of healthcare
workers that we examined previously [10]. The details of
the recruitment and data collection for those participants
were previously described in detail [10].
In that cohort, 116 subjects were RT-PCR positive.
We excluded any subjects with malignancy or using
immunosuppressive drugs. We transformed the duration
between RT-PCR and antibody testing to binomial
data based on a cutoff value of 8 weeks. The RT-PCRpositive control group is formed by recruiting subjects,
using propensity score matching based on age, sex, and
transformed antibody testing duration data with a 1:1
ratio.
Among healthcare workers who did not have a history
of COVID-19, we selected the subjects designated as
“no risk” (healthcare workers who were not attending
the hospital because of administrative changes related to
the pandemic) regarding COVID-19. We excluded any
subjects with malignancy or using immunosuppressive
drugs. Finally, 106 subjects were eligible for selection.
We used age and sex-based propensity score matching to
select subjects from this cohort with a ratio of 1:1.
We used the same laboratory procedures to measure the
antibody levels in those subjects and transplant recipients.
2.3. Data collection
We filled in a standard form for every patient. We used
patient interviews, medical records of the patients, the
hospital’s electronic database, and the national public
health data management system to collect data. Our
form consisted of the following parts; demographics,
clinical data including transplantation history, drug use,
laboratory parameters, history, and clinical data related
to COVID-19, and computed tomography (CT) findings.
We also used the COVID-19 severity index to classify
the patients under five mutually exclusive categories;
asymptomatic or presymptomatic, mild, moderate, severe,
critical illness [15].
2.4. PCR testing and assessment of antibodies
We used the same methods for RT-PCR testing and SARSCoV-2- antibody measurement as described in detail
previously [10,16]. For the detection of COVID-19 RNA,
a commercial RT-PCR kit (Bio-Speedy SARS-CoV-2 RTqPCR kit; Bioeksen R&D Technologies Ltd., İstanbul,
Turkey) was used. For the detection of SARS-CoV-2 IgG
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(antinucleocapsid protein antibodies), chemiluminescent
microparticle immunoassay (Abbott Laboratories, cat. no:
6R86, lot no: 16253FN00) was carried out according to the
manufacturer’s instructions, and samples were run on the
related instrument (ARCHITECT; Abbott Laboratories,
Abbott Park, IL, USA). The qualitative results were
reported by the instrument with a cutoff value of 1.40 S/C
as recommended.
2.5. Therapeutic approach
Antiviral therapy with favipiravir and prophylactic
anticoagulation with low-molecular-weight heparin
were considered in all patients unless contraindicated.
For patients with systemic inflammation, tocilizumab
or anakinra was initiated in addition to high-dose
corticosteroids. Regarding immunosuppressive treatment,
antiproliferative agents were ceased or reduced, calcineurin
inhibitors were maintained stable, dose-reduced or were
completely withdrawn, and corticosteroid doses were
increased based on the disease severity.
2.6. Statistical analysis
Descriptive data were presented as mean ± standard
deviation (SD) and median and interquartile range (IQR)
for the continuous variables and frequency and percentages
(%) for the categorical variables. Continuous variables
were evaluated for normality using the Shapiro-Wilk test.
Kidney transplant recipients and control groups were
compared with an independent samples t-test for normally
distributed variables and the Mann-Whitney U test for
nonnormally distributed variables. Categorical variables
were compared using the chi-square or Fisher’s exact test for
proportion. Multivariate analysis was applied to determine
the association between the antibody level, the groups, and
postinfection duration. All significance tests were twotailed, and values of p <0.05 were considered statistically
significant. All statistical analyses were performed using
the SPSS software version 21 (IBM Corporation, Armonk,
NY, USA).We employed propensity score matching to
balance in the observed baseline covariates and reduce
the bias of treatment effect between the kidney transplant
recipients and control groups. We assumed a ratio of 1:1 on
age and sex with the nearest neighbor matching method.
The propensity score matching was performed using the
RStudio v.4.0.2 software.
Based on previous studies, we accepted the seropositivity
rate following COVID-19 as 60% for transplant patients
and 90% for the general population. Therefore, considering
the percentage from the previous studies, we performed
power analysis (G*Power software version 3.1; HeinrichHeine-Universität Düsseldorf, Düsseldorf, Germany)
with a power of 90% and an error of 0.05 to determine
the minimum sample size for the RT-PCR-positive kidney
transplant recipients and control groups. A minimum
sample size of 42 was estimated for each group.
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3. Results
3.1. Demographic, clinical and laboratory data
We recruited a total of 91 kidney transplant recipients. Of
them, 46 had RT-PCR-confirmed COVID-19, whereas 45
did not have a history of COVID-19 (Table 1). Demographic,
clinical, and laboratory data of the transplant recipients
grouped according to their COVID-19 status are shown
in Table 1. Both groups were similar regarding age and
sex. The etiology of CKD, donor type, and posttransplant
duration were also similar between the two groups.
However, patients with COVID-19 had a higher BMI,
and COVID-19 history in a household member was more
common among them. Other parameters were similar
between the two groups.
The majority (95.6%) of the patients with COVID-19
were symptomatic, and according to computed
tomography of the thorax, 30 patients (65.2%) had
findings compatible with COVID-19. There was no need
for hospitalization in 12 patients (26.1%); the remaining
34 patients (73.9%) were hospitalized, 16 patients (34.8%)
needed oxygen, and three patients (6.5%) were followed
up in the intensive care unit. Two patients (4.3%) needed
intubation. Except for one patient who died on the
26th day of the infection, all patients recovered from
COVID-19. The hospitalization duration was 11.7 ± 7.9
days (median: 9 days, range: from 3 to 38 days). According
to the COVID-19 severity index, two patients (4.3%) were
asymptomatic or presymptomatic, 15 (32.6%) had a mild
illness, 16 (34.8%) had a moderate illness, 10 (21.7%) had a
severe illness, and three (6.5%) had a critical illness.
3.2. Seropositivity
The seropositivity rates and IgG levels among kidney
transplant recipients and controls stratified by the
COVID-19 status are shown in Table 2. Among the
subjects with COVID-19 history, the SARS-Cov-2 IgG
positivity rate (69.6% vs. 78.3%) and IgG level (3.28 vs.
4.59 S/C) of kidney transplant recipients were similar to
those of the control group. The frequency of COVID-19
related symptoms was more common among kidney
transplant recipients than that of the controls; however,
the frequency of pulmonary involvement assessed by
computed tomography was similar between the two
groups. There was no statistically significant difference
between the kidney transplant recipients and controls
in terms of the duration between RT-PCR and antibody
testing (Table 2).
Among the subjects without COVID-19 history, three
kidney transplant recipients had positive IgG antibodies,
and two of them had a history of COVID-19 in a household
member. The SARS-Cov-2 IgG antibody positivity rate
(6.7% vs. 6.7%) and IgG level (0.03 vs. 0.03 S/C) of kidney
transplant recipients were similar to that of the control
group (Table 2).

DİNCER et al. / Turk J Med Sci
Table 1. Demographic, clinical, and laboratory parameters of the kidney transplant recipients according to their COVID-19 status.
COVID-19 (+)
(n = 46)

COVID-19 (–)
(n = 45)

p

Age (years)

46.5 (36.8–55.0)

37.0 (32.0–55.0)

0.194

Male, n (%)

32 (69.6)

27 (60.0)

0.231

Diabetes mellitus, n (%)

5 (10.9)

3 (6.7)

Glomerulonephritis, n (%)

8 (17.4)

11 (24.4)

Others, n (%)

33 (71.7)

31 (68.9)

Living donor, n (%)

36 (78.3)

35 (77.8)

0.600

Transplantation duration (months)

108.0 (48.0–147.0)

84.0 (24.0–132.0)

0.378

COVID-19 in a household member, n (%)

29 (64.4)

3 (6.8)

<0.001

Diabetes, n (%)

13 (28.3)

11 (24.4)

0.431

Hypertension, n (%)

31 (67.4)

26 (57.8)

0.232

BMI (kg/m2)

27.4 ± 4.5

24.7 ± 4.2

0.004

Serum creatinine (mg/dL)

1.28 (1.01–1.53)

1.23 (1.02–1.72)

0.778

e-GFR* (mL/min/1.73 m2)

64.9 ± 24.1

64.6 ± 31.6

0.955

Steroids, n (%)

46 (100.0)

42 (93.3)

0.117

Calcineurin inhibitor, n (%)

43 (93.5)

43 (95.6)

0.511

Mycophenolic acid derivatives, n (%)

41 (89.1)

35 (77.8)

0.119

m-TOR inhibitors, n (%)

4 (8.7)

4 (8.9)

0.631

Azathioprine, n (%)

3 (6.5)

7 (15.6)

0.149

Etiology of CKD
0.599

Comorbidities

Baseline immunosuppression

Values are presented as mean ± SD or as median and IQR.
CKD: chronic kidney disease, BMI: body mass index, m-TOR inhibitors: mechanistic target of rapamycin inhibitors.
*
Calculated using the CKD-EPI formula.
Table 2. Seropositivity among the kidney transplant recipients and controls stratified by their COVID-19 status.
COVID-19 (+)

COVID-19 (–)

Kidney transplant
recipients
(n = 46)

Controls
(n = 46)

p

Kidney transplant
Controls
recipients
(n = 45)
(n = 45)

p

Age (years)

45.9 ± 12.1

41.3 ± 10.2

0.053

37.0 (32.0–55.0)

37.0 (27.5–53.0)

0.534

Male, n (%)

32 (69.6)

32 (69.6)

0.589

27 (60.0)

27 (60.0)

0.585

Symptoms, n (%)

44 (95.7)

36 (78.3)

0.013

NA

NA

NA

CT result, n (%)

30 (65.2)

30 (65.2)

0.558

NA

NA

NA

IgG positivity rate, n (%)

32 (69.6)

36 (78.3)

0.238

3 (6.7)

3 (6.7)

0.662

IgG level (S/C)

3.28 (0.80–5.85)

4.59 (1.61–6.06)

0.499

0.03 (0.02–0.05)

0.03 (0.02–0.09)

0.997

Days following RT-PCR test 49.5 (25.8–70.6)

55.0 (49.3–61.0)

0.392

NA

NA

NA

CT: computed tomography, Ig: immunoglobulin, RT-PCR: reverse transcriptase-polymerase chain reaction.
Values are presented as mean ± SD or as median and IQR.
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3.3. Predictors of antibody positivity
We compared the demographic, clinical, laboratory, and
treatment-related data of the transplant patients who
developed antibodies with those who did not (Table 3).
The median duration between RT-PCR and antibody
testing was shorter (37.5 days [IQR: 20.5–57.8] vs. 82.5
days [IQR: 52.3–105.0], p = 0.01) in patients who had

SARS-Cov-2 IgG antibodies compared to that of the
patients who did not have IgG antibodies. There were
no statistically significant differences between the two
groups regarding demographic, clinical, and laboratory
parameters. Additionally, the cessation rate of different
immunosuppressive drugs was also similar between the
two groups.

Table 3. Comparison of the transplant recipients with and without IgG positivity following RT-PCR-confirmed COVID-19.
IgG-positive
(n = 32)

IgG-negative
(n = 14)

p

Age (years)

47.5 ± 11.1

42.2 ± 13.8

0.172

Male, n (%)

23 (71.9)

9 (64.3)

0.427

Diabetes mellitus, n (%)

4 (12.5)

1 (7.1)

Glomerulonephritis, n (%)

7 (21.9)

1 (7.1)

Others, n (%)

21 (65.6)

12 (85.7)

Living donor, n (%)

24 (75.0)

11 (84.6)

0.392

Transplantation duration (months)

108.9 ± 61.9

88.0 ± 78.8

0.337

Diabetes, n (%)

10 (31.3)

3 (21.4)

0.381

Hypertension, n (%)

22 (68.8)

9 (64.3)

0.511

Coronary artery disease, n (%)

7 (21.9)

5 (35.7)

0.264

Chronic obstructive pulmonary disease, n (%)

2 (6.3)

1 (7.1)

0.673

BMI (kg/m²)

27.6 ± 4.3

26.9 ± 5.1

0.529

Serum creatinine (mg/dL)

1.33 (1.03–1.48)

1.15 (0.87–1.83)

0.867

e-GFR (ml/min/1.73 m²)

63.5 ± 19.0

68.3 ± 33.6

0.537

Asymptomatic - moderate, n (%)

21 (66.0)

12 (85.0)

Severe - critical, n (%)

11 (34.0)

2 (15.0)

Days following RT-PCR test

37.5 (20.5–57.8)

82.5 (52.3–105.0)

0.001

Lowest white blood cell count, (/mm³)

4925.7 ± 1748.0

4596.8 ± 1667.2

0.582

Lowest lymphocytes count, (/mm³)

791.0 ± 603.0

665.4 ± 314.7

0.875

Peak CRP, (mg/dL)

75.8 ± 66.5

74.7 ± 58.0

0.813

Peak ferritin, (ng/mL)

625.0 (249.5–1468.3)

670.1 (236.0–1245.0)

0.839

Fibrinogen, (mg/dL)

447.8 (4.98–649.8)

329.1 (4.76–515.5)

0.439

Peak D-dimer, (µg/mL)

1.03 (0.36–2.94)

0.91 (0.66–2.78)

0.868

Peak procalcitonin, (ng/mL)

1.72 (0.92–127.0)

92.5 (1.13–191.3)

0.146

Peak uric acid, (mg/dL)

8.1 ± 2.1

7.7 ± 2.3

0.622

Stopping MPA, n (%)

17 (53.1)

7 (50.0)

0.549

Stopping CNI, n (%)

3 (9.4)

0 (0.0)

NA

Stopping MPA or CNI, n (%)

18 (56.3)

7 (50.0)

0.471

Etiology of CKD
0.364

Comorbidities

*

Disease severity index
0.286

CKD: chronic kidney disease, BMI: body mass index, RT-PCR: reverse transcriptase-polymerase chain reaction, MPA: mycophenolic
acid derivatives, CNI: calcineurin inhibitor.
*
Calculated using the CKD-EPI formula.
Values are presented as mean ± SD or as median and IQR.

1758

DİNCER et al. / Turk J Med Sci
4. Discussion
We found that kidney transplant recipients developed an
antibody response following COVID-19; 69.6% of the
patients with COVID-19 history had IgG antibodies and
the mean antibody level and the seropositivity rate were
similar to that of the control group. To the best of our
knowledge, the largest report about antibody response
in kidney transplant recipients is from Azzi et al. [9]. In
this report, the researchers examined 69 kidney transplant
recipients who had an RT-PCR-confirmed COVID-19
diagnosis, and 55 (80.0%) of them had a positive antibody
response. The authors used the same test as ours to measure
the antibody levels after a median of 44 days following RTPCR positivity. Hartzell et al. examined anti-SARS-Cov2
IgG antibodies in 16 kidney transplant recipients following
a mean of 16.1 days of RT-PCR testing and reported the
antibody positivity rate as 60.0% and 63.6%, depending on
immunosuppressive drug use [17]. Burack et al. examined
39 kidney transplant recipients and found an antibody
positivity rate of 41.0% [7].
We did not identify any specific risk factors for lack of
seroconversion following COVID-19. However, we noted
a trend toward lower antibody levels in patients who had
a longer postinfection duration. A similar observation was
reported by Benotmane et al. [18] as they examined 29
kidney transplant recipients hospitalized for COVID-19

As an additional analysis, we looked at the correlation
between different laboratory parameters (peak CRP, peak
ferritin, fibrinogen, peak D-dimer, peak procalcitonin,
e-GFR) and the level of SARS-Cov-2 IgG antibodies. There
was no significant correlation between those parameters
(data not shown).
Finally, we analyzed the correlation between the SARSCov-2 IgG antibody levels and the duration between
RT-PCR and antibody testing. The antibody level in
kidney transplant recipients and controls based on the
duration following RT-PCR testing is shown in Figure.
Visual examination revealed that kidney transplant
recipients who had a longer duration between RT-PCR
and antibody testing had lower antibody levels. There
was a significant correlation between the antibody levels
and the duration between RT-PCR and antibody testing
in transplant recipients (r = –0.532, p < 0.001), whereas
no statistically significant correlation was found between
the two parameters in the controls (r = 0.198, p = 0.186).
Additionally, we constructed a multivariate regression
model where we used antibody levels as the dependent
variable and the study group along with the duration
following RT-PCR testing as the independent variables.
This analysis showed that the study group was not an
independent determinant of antibody levels (data not
shown).

50

Transplant

100

150

200

250

Control

Mean antibody level(S/C)

8

6

4

2

0
50

100

150

200

250

Duration between PCR and antibody testing (days)

Figure. SARS-CoV-2 IgG antibody levels among transplant recipients and controls, according
to the duration between RT-PCR and IgG testing.
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and measured antibody levels up to six months after
COVID-19. During the follow-up, 20.7% of the patients
became seronegative. A considerable IgG reduction was
observed in patients treated with calcineurin inhibitors
and steroids. No statistically significant difference was
found regarding disease severity.
In kidney transplant recipients who did not have
positive RT-PCR testing, we found a similar SARS-CoV-2
IgG antibody positivity rate to that in our controls. In
line with our results, a recent study reported that the
seroprevalence rate was 6.6% in asymptomatic people
[19]. In another study, SARS-CoV-2 seroprevalence in
healthy blood donors was reported as 3% [20].
Several studies have reported that kidney transplant
recipients with COVID-19 have a high mortality rate
as high as 40% [1-6]. It has been shown that increasing
age and the presence of comorbid diseases are associated
with an increased risk of mortality [21,22]. In our study,
all kidney transplant recipients recovered except one.
All the patients followed the infectious control measures
rigorously, while most of the infected patients were
younger, had low creatinine levels, and did not have many
comorbidities. We closely followed up those patients and
changed the immunosuppressive therapy as soon as we
were aware of the COVID-19 infection. These factors
might be responsible for the low mortality in our study.
Our study had some limitations. We did not formally
screen all patients; we might have overlooked some
patients who had severe COVID-19 and died. However, it
is unlikely that we missed mild cases because most of the
patients were in close telephone contact with transplant
coordinators during this period. Because of the pandemic,
transplantation activity was stopped. Therefore, our cohort
consists of long-term transplanted patients. The absence
of the patients in the first six months after transplantation
when immunosuppression is the strongest might have
influenced the results. Another limitation of this study was
that the date of infection was defined as the date of PCR

positivity, as opposed to the date of symptom onset. Since
transplant recipients may exhibit prolonged shedding of
the virus, the date of PCR positivity may not always be
an accurate estimate of the infection onset. In addition,
kidney transplant recipients and controls had different
distribution characteristics regarding the duration between
COVID-19 and antibody testing. All the controls were
tested for antibodies at least four weeks, while no controls
were tested beyond 12 weeks postinfection. However, the
distribution of the transplant recipients between different
IgG testing durations was homogenous. Finally, we did not
examine the parameters related to cellular immunity.
In conclusion, kidney transplant recipients seem to
have an antibody response similar to that of the general
population at the early post-COVID-19 period. However,
similar to the general population, there is a tendency
toward lower antibody levels with increasing postinfection
duration. Therefore, we suggest a caution for humoral
immunity in kidney transplant recipients following
COVID-19; at least for three months postinfection. The
follow-up of antibody levels and booster vaccination
might also be warranted.
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